We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up
Read MoreHide Full Article
Key Takeaways
Novo Nordisk partners with OpenAI to integrate AI from drug discovery to commercial operations.
NVO aims to accelerate development timelines and improve R&D productivity using advanced data analysis.
The deal supports cost efficiency, workforce upskilling and a broader AI-driven operating model.
Danish drugmaker Novo Nordisk (NVO - Free Report) has entered a strategic collaboration with OpenAI to integrate advanced artificial intelligence (AI) capabilities across its value chain, from early-stage drug discovery to commercial operations.
The partnership aims to accelerate the development and delivery of new therapies while enhancing operational efficiency through AI-driven insights and automation. The stock gained 3.5% on Tuesday in response to the news.
Rationale Behind the NVO/OpenAI Deal
The collaboration reflects Novo Nordisk’s push to strengthen its innovation engine amid rising competitive pressures in key therapeutic areas such as obesity and diabetes. By leveraging OpenAI’s advanced models to analyze complex biological and clinical datasets, the company aims to identify novel drug candidates more efficiently and shorten development timelines — an increasingly critical factor in maintaining market leadership.
Another key driver is the need to boost productivity across research and development (R&D). Traditional drug discovery processes are time-intensive and resource-heavy, often taking years before viable candidates emerge. Integrating AI into hypothesis testing and pattern recognition allows Novo Nordisk to streamline these processes, enabling faster decision-making and potentially improving success rates in clinical pipelines.
Year to date, NVO shares have lost 22.7% compared with the industry’s 2.7% decline.
Image Source: Zacks Investment Research
Beyond R&D, the partnership is also designed to optimize broader business operations. AI deployment across manufacturing, supply chain and commercial functions could help Novo Nordisk reduce costs, improve forecasting accuracy and enhance distribution efficiency. This end-to-end integration signals a shift toward a more digitally enabled operating model within the organization.
Lastly, the deal underscores a growing industry-wide emphasis on workforce transformation. With OpenAI supporting AI literacy and upskilling initiatives, Novo Nordisk is preparing its global workforce to adopt and scale these technologies more effectively. Combined with strict governance and human oversight frameworks, the company aims to balance innovation with compliance and ethical AI use — an essential consideration in healthcare.
Impact of the OpenAI Deal in NVO’s Competitive Landscape
Eli Lilly (LLY - Free Report) is Novo Nordisk’s nemesis in the cardiometabolic space, which markets its tirzepatide (GLP-1) injections as Mounjaro for type II diabetes (T2D) and Zepbound for obesity. These drugs compete directly with NVO’s semaglutide (GLP-1) injections, Ozempic (for T2D) and Wegovy (for obesity), and have gained significant market share, driven by stronger efficacy and superior commercial execution, fueling rising demand.
As a result, Mounjaro and Zepbound have become LLY’s key top-line drivers, despite being on the market for just over three years. Recently, LLY secured FDA approval for its oral GLP-1 obesity therapy, Foundayo (orforglipron), positioning it as a direct competitor to NVO’s Wegovy pill and potentially giving it the edge to outpace its rival once again.
So, Novo Nordisk is aiming to use its partnership with OpenAI as a long-term strategic lever rather than a near-term fix. By embedding AI across early discovery and development, the company is seeking to build a deeper, more diversified pipeline of next-generation cardiometabolic therapies that could surpass current GLP-1-based treatments in efficacy, convenience and differentiation. If executed effectively, this strategy could enable NVO to sustain leadership in the cardiometabolic space by continuously replenishing its pipeline with high-impact therapies, rather than relying solely on its current blockbuster franchises.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have increased from $2.55 to $2.87. CPRX shares have gained 12.3% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ADMA Biologics’ 2026 EPS have increased from 85 cents to 96 cents. ADMA shares have plummeted 42.5% year to date.
ADMA Biologics’ earnings beat estimates in one of the trailing three quarters, matched once and missed on the remaining occasion, with the average negative surprise being 1.79%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up
Key Takeaways
Danish drugmaker Novo Nordisk (NVO - Free Report) has entered a strategic collaboration with OpenAI to integrate advanced artificial intelligence (AI) capabilities across its value chain, from early-stage drug discovery to commercial operations.
The partnership aims to accelerate the development and delivery of new therapies while enhancing operational efficiency through AI-driven insights and automation. The stock gained 3.5% on Tuesday in response to the news.
Rationale Behind the NVO/OpenAI Deal
The collaboration reflects Novo Nordisk’s push to strengthen its innovation engine amid rising competitive pressures in key therapeutic areas such as obesity and diabetes. By leveraging OpenAI’s advanced models to analyze complex biological and clinical datasets, the company aims to identify novel drug candidates more efficiently and shorten development timelines — an increasingly critical factor in maintaining market leadership.
Another key driver is the need to boost productivity across research and development (R&D). Traditional drug discovery processes are time-intensive and resource-heavy, often taking years before viable candidates emerge. Integrating AI into hypothesis testing and pattern recognition allows Novo Nordisk to streamline these processes, enabling faster decision-making and potentially improving success rates in clinical pipelines.
Year to date, NVO shares have lost 22.7% compared with the industry’s 2.7% decline.
Image Source: Zacks Investment Research
Beyond R&D, the partnership is also designed to optimize broader business operations. AI deployment across manufacturing, supply chain and commercial functions could help Novo Nordisk reduce costs, improve forecasting accuracy and enhance distribution efficiency. This end-to-end integration signals a shift toward a more digitally enabled operating model within the organization.
Lastly, the deal underscores a growing industry-wide emphasis on workforce transformation. With OpenAI supporting AI literacy and upskilling initiatives, Novo Nordisk is preparing its global workforce to adopt and scale these technologies more effectively. Combined with strict governance and human oversight frameworks, the company aims to balance innovation with compliance and ethical AI use — an essential consideration in healthcare.
Impact of the OpenAI Deal in NVO’s Competitive Landscape
Eli Lilly (LLY - Free Report) is Novo Nordisk’s nemesis in the cardiometabolic space, which markets its tirzepatide (GLP-1) injections as Mounjaro for type II diabetes (T2D) and Zepbound for obesity. These drugs compete directly with NVO’s semaglutide (GLP-1) injections, Ozempic (for T2D) and Wegovy (for obesity), and have gained significant market share, driven by stronger efficacy and superior commercial execution, fueling rising demand.
As a result, Mounjaro and Zepbound have become LLY’s key top-line drivers, despite being on the market for just over three years. Recently, LLY secured FDA approval for its oral GLP-1 obesity therapy, Foundayo (orforglipron), positioning it as a direct competitor to NVO’s Wegovy pill and potentially giving it the edge to outpace its rival once again.
So, Novo Nordisk is aiming to use its partnership with OpenAI as a long-term strategic lever rather than a near-term fix. By embedding AI across early discovery and development, the company is seeking to build a deeper, more diversified pipeline of next-generation cardiometabolic therapies that could surpass current GLP-1-based treatments in efficacy, convenience and differentiation. If executed effectively, this strategy could enable NVO to sustain leadership in the cardiometabolic space by continuously replenishing its pipeline with high-impact therapies, rather than relying solely on its current blockbuster franchises.
Novo Nordisk A/S Price and Consensus
Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote
NVO’s Zacks Rank & Stocks to Consider
Novo Nordisk currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and ADMA Biologics (ADMA - Free Report) , sporting a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have increased from $2.55 to $2.87. CPRX shares have gained 12.3% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ADMA Biologics’ 2026 EPS have increased from 85 cents to 96 cents. ADMA shares have plummeted 42.5% year to date.
ADMA Biologics’ earnings beat estimates in one of the trailing three quarters, matched once and missed on the remaining occasion, with the average negative surprise being 1.79%.